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Abstract
Hematopoietic stem cells (HSCs) give rise to all blood and immune cells in the body. These rare cells reside in the hypoxic niche
of the bone marrow (BM) where they are subjected to a complex network of regulatory factors including cellular and molecular
components. To sustain hematopoiesis over the lifetime of an individual, HSCs maintain distinctive metabolic programs, and in
recent years nutritional factors have been increasingly recognized as critical regulators of HSC numbers and functions. Leptin
(LEP), a neuroendocrine messenger, and its receptor (LEPR) are well-known for their immunomodulatory and energy balancing
effects; yet, how LEP/LEPR signaling plays a role in hematopoiesis is under-appreciated. In this review, we summarize and
highlight recent work that demonstrated involvement of LEP/LEPR in hematopoiesis under steady state or stress-associated
situations as well as in pathological conditions such as cardiovascular diseases and malignancies. Although the field is only in its
infancy, these studies suggest evidence of potential clinical applications and proof-of-principle for more in-depth future research.
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Introduction
Discovered in the early 1990s as a key regulator of body
weight and energy expenditure, leptin (LEP) has since
been studied extensively in multidisciplinary fields
[1–5]. Different organs are known producers of LEP in-
cluding adipose tissue, placenta, stomach, etc. Hence, it is
not surprising that LEP, a 16-kDa polypeptide hormone,
exerts both central and peripheral effects by binding to its
surface receptor (LEPR) [6, 7]. LEPR exists in multiple
isoforms as a result of alternative splicing; the long-
isoform (OB-Rb), but not the short isoforms (OB-Ra,
OB-Rc, OB-Rd, OB-Re), has been demonstrated to fully
induce intracellular signaling mostly through the Janus
kinase-signal transducer and activator of transcription
(JAK/STAT) pathway [8, 9]. As a neuroendocrine hor-
mone, the effects of LEP on feeding behaviors are medi-
ated in part through activation of proopiomelanocortin
neurons and inhibition of neuropeptide Y/agouti-related
protein neurons in the hypothalamus [10–13]. However,
its central effects are more intriguingly complex, and in-
volve roles in depression, stress response, dopaminergic
reward circuits, reproduction and thermoregulation. These
topics have been reviewed in depth by others [14–19].
Being secreted mainly by adipocytes in proportion to
body fat mass, LEP also acts as a proinflammatory
adipokine. This is scientifically logical since immune func-
tions are well-known to be tightly linked to nutritional sta-
tus, and LEP is a critical messenger of the body energy
storage throughout the entire life of an individual. It was
reported early on that serum LEP levels and Lep mRNA
expression increases following acute inflammation events
or proinflammatory cytokine injection [20]. In fact, the roles
of LEP and its signaling in mature immune cells have been
well-investigated. For instance, starvation-induced immu-
nosuppression and attenuated T-cell immunity were allevi-
ated by treatment with LEP [21]. Consistent with this, hu-
man LEP acted as a negative regulator of regulatory T
(Treg) cells [22]. Diverse effects of LEP in different im-
mune cells have been reviewed in previous publications
[23–28]. For this review, we focus on roles of LEP/LEPR
in hematopoiesis – under both homeostasis and malignant
conditions – as well as in other stem cell systems.
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LEP/LEPR in Hematopoiesis
LEP/LEPR in Adult Non-malignant Hematopoiesis, Via
Microenvironmental Stromal Cells
In the study of adult hematopoiesis under steady-state
conditions, most work has focused on the roles of
LEPR-expressing stromal cells in the bone marrow (BM)
niches. This is not a great surprise since adipocytes, a
potential major source of BM LEP, are themselves a crit-
ical component of niche cells [29–31]. It is well-
appreciated that hematopoietic stem cells (HSCs) are
maintained, nurtured and regulated by an intricate and
highly dynamic network of both cellular and molecular
factors [32–36]. In order to delineate specific cellular
sources of important growth factors for HSC homeostasis,
a stem cell factor (Scf) green fluorescent protein (Gfp)
knock-in murine model was employed to elegantly dem-
onstrate that SCF from endothelial cells (ECs) and LEPR-
expressing perivascular stromal cells were indispensable
for BM HSC maintenance. In contrast, deletion of SCF
from osteoblasts, Nestin-cre- or hematopoietic cells had
insignificant effects on the BM HSC pool [37]. Notably,
mesenchymal stem/stromal cells (MSCs) (including
LEPR-expressing stromal cells) expressed SCF at higher
levels than endothelial cells [38]. A follow-up study fur-
ther demonstrated that SCF from endothelial cells was
mainly critical for HSCs, whereas SCF from LEPR-
expressing stromal cells was required not only by HSCs
but also by a variety of progenitor cells including com-
mon lymphoid progenitors, common myeloid progenitors,
megakaryocyte-erythrocyte progenitors and other more
differentiated precursor cells [39].
To elucidate roles of niche cells, including LEPR+ stro-
mal cells, in context of hematopoietic recovery post-irra-
diation, a similar approach was utilized but to study the
specific cellular source of pleiotrophin (PTN) rather than
SCF in murine BM [40]. At baseline, using Ptn floxed/
floxed mice (Ptnfl/fl mice) that were crossed with Cre-ex-
pressing mice to conditionally delete Ptn in different cell
types, it was found that under homeostasis LEPR+ stromal
cells were an indispensable source of PTN required for
HSC maintenance. In contrast, conditional deletion of
Ptn from other cell types such as ECs, hematopoietic cells
or osteoblasts did not affect HSC content nor HSC
repopulating function in long-term competitive transplant
assays. Interestingly, when mice were exposed to a sub-
lethal dose of total body irradiation (500 cGy TBI), a shift
in the roles of LEPR+ stromal cells versus vascular endo-
thelial cadherin (VE-cad)+ ECs in hematopoietic recovery
occurred. Even though Ptn deletion from either LEPR+
stromal cells or VE-cad+ ECs resulted in reduction in
numbers of Lin-Sca-1+cKit+ (LSK; containing HSCs and
progenitors) cells and myeloid progenitors by phenotyp-
ing analyses, only PTN from VE-cad+ ECs was required
for recovery of long-term (LT) -HSC. BM cells from ir-
radiated VE-cad-Cre;Ptnfl/fl but not LepR-Cre;Ptnfl/fl mice
exhibited reduced repopulating potential in both primary
and secondary transplants compared to irradiated control
mice.
While these studies highly suggested that LEPR signaling
was functionally critical for adult hematopoiesis particularly
inthestromalniche,itwouldalsobemeaningfulandclinically
relevant toknowwhether theLEPligand itselfmediated these
effects or if there were alternative cytokine cross-signaling
pathways that acted through LEPR, for example like
Interleukin (IL)-6 signaling [41, 42]. One reason being that
obesity is a risk factor for hematologicmalignancies. Patients
with obesity have increasedmortality rate and hematopoietic
cell transplant (HCT)- associated complications. Moreover,
altered LEP signaling has been well-documented in obesity
[43]. In fact, the indirect involvement of LEP signaling on
hematopoietic output by modulating BM stromal cells in the
context of exercise and chronic inflammation such as in ath-
erosclerosis and cardiovascular diseases has been reported
[44]. Voluntary exercise induced HSC/hematopoietic pro-
genitor cell (HPC) quiescent-promoting niche factors only
inLEPR+stromal cells, but not in other niche cellular compo-
nentswhilereducingadipose-tissue-derivedLEPproduction.
Also, LEP supplementation during exercise increased levels
of circulating leukocytes, LSK cell proliferation and de-
creased gene expression of BM Angpt1, Cxcl12 and Vcam1,
which are important for HSC/HPC quiescence and retention




in stromal cells usingPrrx1-creERT2;Leprfl/flmice showed a
reduction inLSKcellproliferationandcirculating leukocytes
while enhancing expression of HSC maintenance niche fac-
tors [44]. This resembled the phenotype in exercising mice.
Absence of LEP signaling in stromal cells of these mice alle-
viated the rise in LSK cell proliferation and systemic leuko-
cytosis post-myocardial infarction (MI) [44].Treatmentwith
LEP-neutralizing antibody 30 min after MI reduced BM
colony-forming granulocyte-macrophage progenitor cell
proliferation andmonocytes in the blood and at the site of the
infarct. This resulted in less inflammation and fibrosis and
helped accelerate recovery. Similar results were observed in
adifferentmodelofatherosclerosis[44].Thesewell-designed
studies highlighted the significant roles that LEPR-
expressing stromal cells play in both steady-state and patho-
logicalhematopoiesis.Even thoughLEP/LEPRinvolvement
in potential various pathological conditions in the context of
hematopoiesis is only in its infancy, these findingsmay have
therapeutic potential.
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LEP/LEPR in Adult HSCs
Not long after discoveries of LEP and its receptor, a novel
sequence was cloned, namely B219, which was found in
primitive hematopoietic cells isolated from the yolk sac, early
fetal liver and some lymphohematopoietic cell lines. The se-
quence was expressed in at least four isoforms including one
that resembled the recently published LEPR; its amino acid
sequence shared similarity with granulocyte colony stimulat-
ing factor (G-CSF) receptor, gp130 and the leukemia inhibi-
tory factor (LIF) receptor [1, 45]. In that same year, cloning of
different isoforms of LEPR from human hematopoietic cell
cDNA libraries were reported [46]. Ectopic expression of
the long isoform OB-Rb in murine Ba/F3 and M1 cell lines
respectively induced cell proliferation and differentiation.
However, it was not clear whether LEP had effects on endog-
enously expressed LEPR and if so, in which hematopoietic
cell populations. LEP enhanced cytokine production and
phagocytosis by murine peritoneal macrophage [46]. While
these findings were limited to in vitro work, they spurred
interest in more recent years in the study of LEP and its re-
ceptor in the field of hematology.
Beyond the scope of LEPR in the BM microenvironment,
the functional properties of LEPR-expressing HSCs were
characterized in a recent publication (Fig. 1) [47]. Even
though it’s been known for years that a fraction of human
CD34+ cells and mouse hematopoietic cells expressed
LEPR, there was a gap in knowledge of how these cells might
be functionally different from their LEPR− counterparts.
LEPR+LSK cells, although occupying a much smaller per-
centage out of total LSK cells, were significantly enriched
for both colony-forming progenitors and repopulating LT-
HSC as shown by higher engraftment and robust self-
renewing capacity in both primary and secondary competitive
transplant assays [47]. Using a limiting dilution assay,
LEPR+SLAM HSCs (LSK CD150+CD48−) were compared
to LEPR−SLAM HSCs on a cell-to-cell basis. LEPR+
SLAM HSCs consistently engrafted significantly higher than
LEPR− SLAM HSCs with a higher frequency of competitive
repopulating units (CRUs, a measure of functional engrafting
HSCs; on average, Poisson Statistical Analyses showed
LEPR+SLAM HSCs contained approximately 90 times more
CRUs than LEPR−SLAMHSCs); multilineage differentiation
capabilities were similar.
Consistent with previous findings that CD45+ hematopoi-
etic cells hardly expressed the long isoform of LepR (or OB-
Rb) [48], the majority of Lepr mRNA expressed by
LEPR+SLAM HSCs and LEPR+ SLAM multipotent progen-
itor (MPP) (LSK CD150−CD48−) under steady-state were
OB-Ra andOB-Rc in a bulk RNA-seq transcriptomic analysis.
As noted in the study, the cells were sorted from freshly iso-
lated BM from healthy young adult mice directly into lysis
buffer for RNA extraction; hence, the isoforms of Lepr
expressed in these cells might not exactly be the same as in
those upon transplanted into a lethally irradiated host [47].
Whether LEPR+HSCs express the long isoform (OB-Rb) at
any stages during development or under other circumstances
such as during stress hematopoiesis remains to be determined.
Using a data-driven nonbiased approach, Fast Gene Set
Enrichment Analysis (FGSEA) revealed the top hit pathways
in LEPR+SLAM HSCs, compared to LEPR− SLAM HSCs,
were Type-I Interferon and Interferon-gamma (IFN-γ) re-
sponse pathways. In addition, among the top differential gene
expression candidates were Relb and c-Rel; both are subunits
of the nuclear factor kappa b (NF-κB) pathway. The IFN-γ
proinflammatory response pathway and NF-κB signaling
have been implicated in development of embryonic HSCs
[49, 50]. Although these associations might suggest and ex-
plain a potential embryonic-like transcriptomic signature and
the highly engrafting functional characteristic of LEPR+ LT-
HSCs, in-depth mechanistic studies are warranted to shed
light into the developmental origin of this subset of HSCs.
Perhaps, it will be therapeutically relevant to determine
whether LEP signaling plays a role in the transition of
hemogenic ECs into HSCs in terms of both numbers and
functions since the maternal status of energy storage, which
is reflected and regulated by LEP levels, might influence he-
matopoiesis in the embryo. On the other hand, LEP resistance
has been suggested to occur during aging, and if LEPR sig-
naling has any role(s) in hematopoiesis it will be interesting to
determine how aging may differentially affect LEPR+HSCs
vs. LEPR−HSCs phenotypically and functionally in terms of
engraftment and lineage choices [51, 52].
To the best of our knowledge, there has not been any evi-
dences demonstrating direct effects of LEP/LEPR on HSCs or
more immature progenitors in the literature. However, as men-
tioned earlier the roles of LEP/LEPR signaling in mature im-
mune cells are well-established [24, 27], and because immune
cells constitute a distinguishable hematopoietic cell niche [53,
54] it is conceivable that LEP could potentially regulate HSC/
HPC numbers and functions indirectly through the immune
system especially in the context of stress hematopoiesis such
as post-irradiation or in acute infections.
LEP exerts diverse effects on both innate and adaptive
immune cells, and in general it is considered a proinflamma-
tory cytokine with certain exceptions including its inhibitory
effects on natural killer cells upon extensive exposure [55].
Within the adaptive immune branch, LEP is critical for CD4+
T cell homeostasis and activation [56]. Interestingly, studies
suggested that CD4+ T cells are important for hematopoiesis
as well as successful engraftment of allogeneic BM [57, 58].
This poses a potential question that is whether LEP by acti-
vating CD4+ T cell can facilitate HSC reconstitution in the
context of HCT. On the other hand, LEP negatively regulates
Treg cells [59], but Treg cells were shown to play a crucial
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role in maintaining HSC quiescence [60]. Hence, it is possible
that prolonged LEP stimulation could actually be detrimental
to HSCs, and this could explain why obese patients, who are
typically presented with hyperleptinemia, have a worse prog-
nosis after allogeneic BM HCT [61]. Perhaps, the timing and
dosing of LEP stimulation during a transplantation are what
determines the outcomes – while the proinflammatory effects
of LEP on immune cells could be important to the enhanced
engraftment of HSCs, yet too much of it would be
counterproductive.
During acute infections, LEP levels increased [62], and
LEP has been well-characterized to activate innate immune
cells as the first line of defense. Its effects include both direct
and indirect involvements such as enhancement of phagocy-
tosis bymacrophages [63], stimulating secretion of proinflam-
matory cytokines including tumor necrosis factor alpha
(TNFα), IL-1β and IL-6 by monocytes [64], promoting neu-
trophil infiltration through chemotactic migration, and so on.
Of note, innate myeloid cells are generally short-lived, so
continuous increased replenishment from the BM through dif-
ferentiation of myeloid precursors is needed. It is possible that
LEP-mediated production of proinflammatory cytokines in
response to an infection is amongst several mechanisms that
create a feedback loop sustaining the so-called ‘emergency
myeloipoiesis.’ Unfortunately, if this process keeps going ex-
cessively and/or is deregulated like what happens in cytokine-
release syndrome (CRS), such immunological responses be-
come pathological and can cause severe or life-threatening
sequelae [65]. The extent to which LEP is involved in this
immunopathological condition can be potentially a question
of great interest particularly in the ongoing pandemic of coro-
navirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), as being
overweight or obese has been consistently associated with
more severe cases of COVID-19 [66–69]. In fact, chronically
elevated levels of LEP in obesity and its consequential en-
hancement of inflammation both locally at the site of infection
and systemically have been suggested to be at least partially
responsible for this clinical observation [70–72]. It can be
logically speculated that the enhanced proinflammatory ef-
fects of LEP at baseline in obesity helps exacerbates the
virus-mediated cytokine storm. Interestingly, angiotensin-
converting enzyme 2, the only so far known receptor for
SARS-CoV-2, has been recently reported to be expressed by
human cord blood-derived HSCs [73, 74]. Exposure to
SARS-CoV-2 spike protein can activate the Nlrp3
inflammasome, which has been proposed to initiate CRS
[73, 75], as well as negatively regulate HSC/HPC functional
properties in vitro [74]. This is very important because the
long-term effects of SARS-CoV-2 is still a subject of ongoing
investigations, and it could potentially affect not only the in-
fected individuals but also recipients of cellular therapies [76,
77]. To further understand how SARS-CoV-2 impacts hema-
topoiesis in individuals with aberrant LEP signaling including
obese patients, future research is warranted because the effects
of LEP could be multi-layered through its broad involvement
in both immunity as well as metabolism.
LEP/LEPR in Hematologic Malignancies – the Known
and Unknown
There have been numerous studies in patients with both my-
eloid and lymphoid malignancies that looked at changes in
plasma LEP levels during the course of the diseases and
showed leukemic cells expressing leptin receptor isoforms
[78–87]. Unfortunately, the majority of these publications
did not determine whether there were any distinct functional
properties of LEPR-expressing leukemic cells or if LEP
Fig. 1 LEPR+HSCs under steady state condition [47] becomes
‘activated’ in post-injury recovery (hypothetical). a Under homeostasis
LEPR+ HSCs only express short isoforms of Lepr (OB-Ra&OB-Rc) and
are characterized by a proinflammatory transcriptomic profile. b
Hypothetically, LEPR+HSCs may express long isoform of Lepr (OB-
Rb) as a result of stress-associated activation
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signaling played a role in human leukemia pathogenesis and
maintenance, and if so, how. In this section, we highlight
some of the work which provided proof-of-principle evidence
of LEP and its receptor being possibly involved to some extent
in different types of leukemias using: patient-derived samples,
murine models and xenograft studies.
As early as 1999, using reverse-transcriptase polymerase
chain reaction to study gene expression levels, it was demon-
strated that approximately 50% of collected patient specimens
of either newly diagnosed primary or secondary acute myeloid
leukemia (AML) expressed higher levels of the long isoform,
than the short isoform, of LEPR. This was also true for prima-
ry and recurrent acute promyelocytic leukemia. In contrast,
only the short isoform could be found in healthy human
promyelocytes (defined as CD34−CD33+ or CD34−CD13+).
LEPR was not detected in chronic or acute lymphocytic leu-
kemic cells [78]. Patient-derived myeloid leukemic blasts and
leukemic cell lines proliferated at low levels when treated with
human recombinant LEP alone and significantly at higher
levels in the presence of IL-3, G-CSF, or SCF [78].
Similarly, another paper characterized in vitro effects of
LEP on cultured human AML blasts and compared systemic
LEP levels in AML patients with healthy controls [88]. Serum
LEP concentrations were significantly lower in untreated
AML patients, but were not significantly different for patients
in remission compared to normal subjects. Whether or not this
change in serum LEP levels might have been related to the
treatments was not further investigated. The authors [88] then
looked at in vitro responses of patient-derived AML blasts
(mixed CD34+ and CD34− leukemic cells) to LEP treatment
and found that LEP significantly increased blast cell prolifer-
ation and secretion of proinflammatory cytokines including
IL-1β, IL-6, TNFα and granulocyte-macrophage colony-
stimulating factor (GM-CSF) in a subset of patients.
Notably, effects of LEP were observed at supraphysiological
levels (2 ug/mL), so it is still unclear how these blasts might
have behaved differently in response to physiological levels of
leptin in vivo. Plus, systemic LEP concentrations may signif-
icantly differ from local sources such as in the leukemic BM
niche. This was followed up with colony-forming unit assays
using the same LEP concentration of 2 ug/mL in two different
settings. Specifically, AML blasts were cultured for 7 days
with or without LEP before being washed and plated, or the
cells were plated directly in the presence or absence of LEP
with GM-CSF and Erythropoietin. LEP was found to have
minimal effects on colony formation, blast differentiation
and apoptotic activity. However, results varied among patient
samples. Overall, while these two studies were of some inter-
est and suggested a potential new therapeutic target involving
LEPR signaling in AML, the scope was limited to in vitro
work, and the sizes of patient samples were relatively small.
Thus, more in-depth future work with rigorous in vivo func-
tional assessments and mechanistic insights are warranted.
In contrast to the above studies, more recent work [89]
demonstrated that LEPR signaling mediated the protective
effects of fasting on acute lymphoblastic leukemia (ALL),
but not AML, cells. The study provided therapeutically rele-
vant mechanisms. Using the activated Notch1 T-ALL model,
the N-Myc B-ALL model and the MLL-AF9 AML model, it
was found that fasting significantly suppressed ALL, but not
AML, development by promoting blast cell differentiation
and hence prolonged leukemia-induced mouse survival.
RNA-seq analyses of leukemic B-ALL cells revealed expres-
sion levels of multiple cytokine receptors upregulated by
fasting including Lepr and its major downstream effector,
the transcription factor Stat3. This study [89] also pointed
out that expression of LEPR was positively correlated to sur-
vival rates in patients with pre-B-ALL. It was confirmed that
B-ALL, T-ALL and AML leukemic cells express the long
isoform OB-Rb; likewise, fasting did not upregulate Lepr in
AML as it did in B-ALL and T-ALL cells. To investigate
potential role(s) that LEPR signaling plays in ALL develop-
ment, WT mice were transplanted with N-Myc-infected BM
Lin− cells that either came fromWT (Lepr+/+) or Lepr−/− (db/
db) mice. Recipient mice that received Lepr−/− leukemia-
transformed BM cells developed B-ALL at a significantly
faster rate, had higher multi-organ leukemic burden and lower
survival rate. The Lepr−/− group had a higher percentage of
B220+CD43+ precursors and a lower percentage of differen-
tiated B220+IgM+ cells, which suggested that LEPR signaling
was critical for the differentiation of B-ALL cells. Similar
results were observed in T-ALL but not in AML models
[89]. Furthermore, the investigators repeated these experi-
ments, but recipient mice were fasted for 48 h upon attaining
about 60 % of leukemic-transformed GFP+ cells in PB.
Consistent with initial findings, fasting attenuated percentages
of GFP+ leukemic cells and increased percentages of differen-
tiated IgM+ cells in the WT (Lepr+/+), but not in Lepr−/−,
group. This confirmed that the anti-leukemic effects of fasting
were mediated through LEPR signaling [89].
Mechanistically, LEPR overexpression in B-ALL cells led
to upregulation of key transcription factors in B cell terminal
differentiation including XBP1 and PRDM1 [89].
Overexpression of Prdm1 blocked B-ALL development, and
knockdown of Prdm1 inhibited the anti-leukemic effect of
LEPR overexpression in B-ALL. In silico analyses of patient
databases showed that LEPR signaling and its related genes
were positively correlated with better outcome and survival in
pre-B-ALL leukemia. It was also demonstrated that fasting
negatively regulated B-ALL development in a xenograft mod-
el transplanted with human pre-B-ALL cell line NALM-6,
and it did so by upregulating LEPR expression [89].
A Lep−/− mouse model (Ob/Ob) was used to investigate
potential effects of obesity on development of AML from
myeloid dysplastic syndrome (MDS) and its associated mor-
tality rate [90]. Using BM from NUP98-HOXD13 transgenic
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mice, a model of MDS, compared to lean WT controls, obese
Lep−/− recipient mice had significantly higher survival rates,
and opposite to the researchers’ hypothesis these mice did not
have increased risk of AML transformation. While Lep−/−
recipient mice transplanted with NUP98-HOXD13 BM had
more severe monocytosis, it was suggested that their expand-
ed adipose tissue was capable of harboring more myeloid
cells, and hence reduced their detrimental accumulation in
other vital organs such as the liver [90]. Even though the
authors rationalized their reasons for excluding the potential
effects of Lep knockout on their findings, it would have been
of more interest if the phenotypes were consistent in a differ-
ent model of obesity and NUP98-HOXD13 induced MDS.
Furthermore, considering that obese individuals are at higher
risk for leukemia development and obese children afflicted
with leukemia have increased mortality rate [61, 91–93], this
study posed discrepancies between mice and humans, and
thus requires future in-depth reevaluation.
In addition to being present on leukemic hematopoietic
lineage cells, LEPR-expressing stromal cells have also been
demonstrated to be involved in BM fibrosis of primary mye-
lofibrosis (PMF), a subtype of myeloproliferative neoplasms
[94]. While LEPR+ mesenchymal stromal cells have been
studied more extensively in normal hematopoiesis, the malig-
nancy transformation potential of these prominent niche cells
is far less understood. It was demonstrated that these cells
were functionally and molecularly altered during the progres-
sion of thrombopoietin (TPO)-overexpressing-induced PMF
[94]. Specifically, by using different genetic fate mapping
models it was discovered that as the mice developed PMF,
LEPR+ stromal cells significantly expanded in numbers and
increased production of collagen, which led to BM hemato-
poietic failure, fibrosis and extramedullary hematopoiesis. In
line with this finding, gene expression analyses demonstrated
that LEPR+ stromal cells down-regulated HSC supporting
growth factors including Cxcl12 and Scf while up-regulating
genes involved in fibrotic conversion. Importantly, mechanis-
tic studies pinpointed platelet-derived growth factor receptor
alpha (PDGFRα) as the key player in the pathogenesis of
bone marrow fibrosis caused by LEPR+ stromal cells. This
was therapeutically relevant since imatinib, an inhibitor of
different tyrosine kinases including PDGFRα, was shown to
lessen fibrosis in this model of PMF [94]. Even though the
study focused on PMF, it has opened up a new area for future
studies into microenvironmental niche cells in other hemato-
logical malignancies, which is arguably just as important as
studying the leukemic cells themselves.
LEP/LEPR in Other Stem Cells
The therapeutic value of LEP/LEPR in different stem cell-
based systems have been explored over decades. Here, we
describe some of the recent work that provided evidence of
how LEP and its receptor regulate stem cell functions, with
some showing potential clinical applications.
Thus far, most of the studies on LEP/LEPR in stem cell
biology under homeostasis have not fully addressed mecha-
nistically whether and how LEP/LEPR directly regulates stem
cell functions. It was recently reported using mass
spectrometry-based global proteomic analyses that LepR−/−
(or db/db) mouse embryonic fibroblasts had increased levels
of phosphorylated extracellular regulated MAP kinase
(ERK)1/2, regulatory associated protein of mTOR
(RAPTOR) and mitogen-activated protein kinase kinase
(MEK)1/2 with the most differentially regulated pathways
involving mitochondrial dysfunction and oxidative phosphor-
ylation [95]. Likewise, induced pluripotent stem cells (iPSCs)
derived from db/db mice, and hence carrying the Lepr muta-
tion, exhibited significant lowered protein levels of the
pluripotency markers OCT4 and NANOG. db/db iPSCs also
revealed a proteomic profile that involved pathways regulat-
ing mitochondrial functions, protein synthesis (including up-
regulation of eukaryotic translation initiation factor 4e
(EIF4E) and EIF4G) and pluripotency [95]. Molecularly, db/
db iPSCs were demonstrated to have a reduction in STAT3
phosphorylation in response to LEP treatment even though at
baseline there was no difference as compared to control
iPSCs. Chromatin immunoprecipitation analysis revealed en-
richment of Stat3 binding regions on the promoter of Eif4e of
db/db iPSCs, hence leading to enhanced protein synthesis as
shown by a higher polysome/monosome ratio in polysome
profiling study and an increased basal oxygen consumption
rate in metabolic profiling study. Overall, these findings sug-
gest a role(s) of LEP/LEPR both in embryonic stem cell de-
velopment and in regulating pluripotency-associated genes.
For future work, it will be interesting and relevant to investi-
gate further functional characteristics of stem cells with
disrupted LEP/LEPR signaling. For instance, how would it
affect the ability of the cells to differentiate versus maintaining
a stem-like state? Would it affect one or multiple lineages and
to which extent? Would the effect(s) be reversible? Would the
effect(s) be similar under steady state versus pathological
conditions?
In a highly mechanistic study it was demonstrated that
production of LEP induced by hypoxia preconditioning mod-
ulated the level of mitochondrial fusion protein OPA1, and
hence improved human MSC survival and its therapeutic ef-
fects under ischemic conditions [96]. While the study showed
that overexpression of LEP in human MSCs promoted their
in vivo therapeutic effects including enhanced cardiac function
and increased angiogenesis in cardiac infarction, it was un-
clear whether endogenous circulating LEP played any role,
and if so, would endogenous LEP also act mainly through
the GSK3/OMA1/OPA1 pathway? In a follow up study
[97], it was shown that LEP increased glycolysis in MSCs
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by upregulating the glucose transporter sodium-glucose
symporter 1 (SGLT1), and OPA1 was required for the effect
of leptin on glycolysis. However, it was not well-addressed
how OPA1 could be involved in the enhanced expression of
SGLT1 [97]. Notably, LEP has been well-known for its an-
giogenic effect, and was shown to increase endothelial cell
differentiation from murine embryonic stem cells [98, 99].
Furthermore, obese patients who have increased risk for car-
diovascular diseases may be more likely to have higher sys-
temic LEP levels and LEP resistance. Considering that this
could also have a negative impact in vivo [44], it is important
to weigh potential risks versus benefits as to how the cells may
be preconditioned before transplantation.
On the other hand, LEP signaling has been studied exten-
sively in context of solid tumor cancer stem cells (CSCs),
particularly in breast cancer stem cells (BCSCs) [100, 101].
CSCs represent one of the key challenges to cancer treat-
ments; hence, understanding how CSCs are initiated and
maintained by the tumor microenvironment will have an im-
pact on development of more effective therapies. It has been
demonstrated that LEPRb maintained stem-cell-like charac-
teristics of triple negative breast cancer cells (TNBC) by in-
ducing expression of stem cell self-renewal transcription fac-
tors OCT4, SOX2 and NANOG [102]. Using a NANOG
promoter-driven GFP activity readout, it was observed that
mouse LEPR when introduced into human TNBC MDA-
MB-231 and HCC70 non-CSCs induced NANOG expression
[103]. Two other markers of CSCs SOX2 and OCT4 were
also expressed at higher levels in LEPR-expressing non-
CSCs as compared to control non-CSCs; this suggested that
overexpression of LEPRb was sufficient to convert non-CSCs
into CSCs. Still, it was not clear whether in situ non-CSCs can
naturally acquire LEPRb expression to become CSCs and if
the transition is reversible or not. While LEP signaling can
have multiple downstream effectors, the authors showed that
LEPRb specifically activated Tyr1077 and Tyr1138 phos-
phorylation, which in turn transactivated JAK2/STAT3, a ma-
jor signaling pathway of LEPRb activation.
In a more mechanistic study, it was demonstrated that
the pan-JAK inhibitor AZD1480 decreased viability of
HCC1937 CSCs as compared to its non-CSC counterpart
and suppressed tumorsphere formation from MCF7 CSCs
[104]. To understand molecular pathways that governed
this phenomenon, they performed RNAseq analyses on
AZD1480-treated MCF7 tumorsphere cells and discov-
ered that genes involved in lipid metabolism were down-
regulated [104]. Mechanistically, STAT3 modulated ex-
pression of genes involved in fatty acid oxidation (FAO)
including the rate-limiting enzyme carnitinepalmitoyl
transferase 1 (CPT1), which was required to maintain tu-
mor cells in a stem-cell-like state. In line with this, inhi-
bition of STAT3 in BCSCs reduced their self-renewing
capacity. To further explore which upstream regulator af-
fects STAT3/FAO pathway in BCSCs, they performed an
adipokine array using breast adipocyte-conditioned medi-
um. Among the most abundantly expressed adipokines
was LEP. By using quantitative real time polymerase
chain reaction and flow cytometry analyses, the only
adipokine receptor detected at increased levels in the
patient-derived BBM2 and BBM3 tumorsphere cells was
LEPR. Consistent with this finding and the fact that LEPR
signaling is known to activate JAK2/STAT3 pathway,
Table 1 LEP/LEPR in hematopoiesis. What is known?
LEP/LEPR in BM mesenchymal
stem/stromal cells (MSCs)
• LEPR+ BM MSCs were an indispensable source of SCF (37, 38) and PTN (40) that were required to
maintain HSC homeostasis.
• SCF derived from LEPR+ BM MSCs were critical for both HSCs and progenitor cells under steady state
(39).
• Exercise induced expression of niche factors only in LEPR+ BMMSCs while leptin supplementation
reversed this effect (44).
LEP/LEPR in HSC/HPCs • Isoforms of LEPR were found in both murine and human primitive hematopoietic cells (45, 47).
• LEP signaling through LEPR+ BM MSCs induced LSK proliferation and hematopoietic output in
post-myocardial infarction and atherosclerosis (44).
• LEPR+LSK cells were highly enriched for functional self-renewing LT-HSCs, and LEPR+HSCs repre-
sented a subset of more robustly repopulating LT-HSCs as compared to LEPR−HSCs (47).
LEP/LEPR in hematologic malignancies • A significant proportion of patient-derived leukemia samples expressed isoforms of LEPR (78–85).
• LEP induced myeloid leukemic blasts and cell lines to proliferate at low level while enhancing effects of
IL-3, G-CSF or SCF (78).
•At supraphysiological concentration, LEP increased patient-derived AML blast proliferation and secretion
of IL-6, TNFα, IL-1β and GM-CSF (88).
• LEPR signaling mediated the anti-leukemic protective effects of fasting in B-ALL and T-ALL but not
AML models by promoting blast cell differentiation (89).
• LEPR+ MSC alterations (e.g. lower expression of niche factors, upregulating genes involved in fibrosis)
played a key role in the pathogenesis of PMF (94).
Numbers in parenthesis ( ) refer to papers where this information can be found
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further experiments revealed that adding LEP to culture
media increased tumorsphere formation, as well as phos-
phorylation of JAK2 and STAT3. Likewise, treatment
with LEP neutralizing antibody reversed the increase in
expression of CPT1B and ACADM, both enzymes in-
volved in the FAO pathway, and reduced the percentage
of BCSCs in the breast tumors. In fact, in patient tumor
samples it was found that chemoresistant metastatic breast
tumor sections expressed higher level of LEPR with
LEPR-positive cells having increased CPT1B expression.
Altogether, these in-depth mechanistic studies using
patient-derived samples strongly suggested that leptin re-
ceptor and its downstream effectors JAK2/STAT3/CPT1
may be potential drug targets that will specifically eradi-
cate the chemoresistant BCSCs.
Concluding Remarks
LEP and LEPR signaling play important modulatory roles
throughout an organism’s life from conception to old age.
LEPR resistance is well-recognized in obesity and aging [43,
105]. With a persistently increased prevalence of obesity and
growth in the elderly populations worldwide, understanding
how the different pathological conditions including hemato-
logic malignancies and hematopoietic transplantation-
associated complications biasedly affected these subsets of
patients has become even more important. In this report, we
noted and highlighted the work that provided proof-of-
principle evidence for more future in-depth studies. A sum-
mary of what is known about LEP and LEPR in hematopoie-
sis can be found in Table 1. In brief, LEP/LEPR have been
suggested to regulate stem cell numbers and functions partic-
ularly in the hematopoietic system under homeostasis, as well
as post-injury regeneration and malignant transformation.
Even though there are still some discrepancies between differ-
ent studies or between animal and human data especially
regarding LEPR and leukemic cells, the findings lay a strong
foundation and create interesting questions to be answered in
follow-up studies (Table 2). Future work that elucidates and
provides insight into mechanisms of LEP/LEPR interactions
is warranted and may provide potential implications for ther-
apeutic approaches to enhance healthcare.
Abbreviations ALL, acute lymphoblastic leukemia; AML, acute mye-
loid leukemia; BCSC, breast cancer stem cell; BM, bone marrow;
COVID-19, coronavirus disease 2019; CPT1, carnitinepalmitoyl transfer-
ase 1; CRS, cytokine release syndrome; CRU, competitive repopulating
unit; CSC, cancer stem cell; EC, endothelial cell; EIF, eukaryotic initia-
tion factor; ERK, extracellular regulated MAP kinase; FAO, fatty acid
oxidation; FGSEA, fast gene set enrichment analysis; G-CSF, granulo-
cyte colony stimulating factor; GFP, green fluorescence protein; GM-
CSF, granulocyte-macrophage colony-stimulating factor; HCT, hemato-
poietic cell transplant; HPC, hematopoietic progenitor cell; HSC, hema-
topoietic stem cell; IFN, interferon; IL, interleukin; iPSC, induced plurip-
otent stem cell; JAK/STAT, Janus kinase-signal transducer and activator
of transcription; LEP, leptin; LEPR, leptin receptor; LIF, leukemia inhib-
itory factor; LSK, Lineage(Lin)−Sca1+cKit+; LT, long-term; MDS, mye-
loid dysplastic syndrome;MEK,Mitogen-activated protein kinase kinase;
MI, myocardial infarction; MPP, multipotent progenitor; MSC, mesen-
chymal stem cell; NF-κB, nuclear factor kappa b; PDGFRα, platelet-
derived growth factor receptor alpha; PMF, primary myelofibrosis;
PRDM1, PR domain containing 1; PTN, pleiotrophin; RAPTOR, regu-
latory associated protein of mTOR; SARS-CoV-2, severe acute respira-
tory syndrome coronavirus 2; SCF, stem cell factor; SGLT1, sodium-
glucose symporter 1; TNBC, triple negative breast cancer cell; TNF,
tumor necrosis factor; TPO, thrombopoietin; Treg, regulatory T; VE-
cad, vascular endothelial cadherin; WT, wild-type; XBP1, X-box binding
protein 1
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Table 2 LEP/LEPR in hematopoiesis. What’s next?
Non-pathological
conditions
o Molecular mechanisms by which LEPR signaling in stromal cells regulate expression of important niche factors under
steady state vs. post-injury hematopoietic regeneration.
o Is LEPR on HSCs just a surface marker or is LEPR functional especially in context of post-injury recovery?
o Does the sources of LEP (e.g. systemic vs. local BM adipocytes) matter?
o Does LEP/LEPR play any roles in the specification of HSCs during embryonic period up until birth? And if so, by which
mechanisms? And how does maternal and fetal leptin production affect these processes?
o How may aging exert differential effects on LEPR+ stromal cells or LEPR+ HSCs vs. LEPR−cells?
o Does LEP signal through other cytokine receptor(s) in the same family that may be present on BMMSCs and/or HSCs?
Pathological
conditions/leukemia
o Do LEPR+ HSCs/HPCs possess different potentials for leukemic transformation from LEPR−cells? How can other risk
factors possibly further modulate the difference?
o There were discrepancies between MDS model using Lep−/− mice and patient studies. Was this actually due to obesity
alone as suggested or the absence of LEP played additional roles?
o While healthy mouse HSCs/MPPs were reported to express predominantly only the short isoforms under steady state, by
which mechanisms the leukemic blast cells for both myeloid and lymphoid malignancies reactivated LEPR long iso-
form? And how does this affect their functional behaviors? Implications for treatments?
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